Compare NP & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | ADPT |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2025 | 2019 |
| Metric | NP | ADPT |
|---|---|---|
| Price | $28.21 | $25.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $34.00 | $29.81 |
| AVG Volume (30 Days) | 471.5K | ★ 2.0M |
| Earning Date | 10-20-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $26.63 | $5.94 |
| Revenue Next Year | $17.59 | $22.42 |
| P/E Ratio | $180.44 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $14.78 | $12.00 |
| 52 Week High | $35.15 | $30.74 |
| Indicator | NP | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 46.87 |
| Support Level | $26.86 | $23.73 |
| Resistance Level | $29.01 | $26.51 |
| Average True Range (ATR) | 1.03 | 1.55 |
| MACD | 0.14 | -0.23 |
| Stochastic Oscillator | 37.29 | 21.68 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.